The Implication of Dropping Race from the MDRD Equation to Estimate GFR in an African American-Only Cohort

Abstract

The widely used Modification of Diet in Renal Disease (MDRD) formula adapts a 1.212 multiplier for individuals who are identified as African Americans (AAs) or Blacks, which leads to a higher GFR estimation. As it stands, AAs have a lower prevalence of chronic kidney disease (CKD) but higher incidence of end-stage renal disease (ESRD) compared with Whites. Many hypotheses have been postulated to explain this paradox, but the imprecision of the GFR estimation with race-adaptation could be contributory. We performed a single-center, longitudinal, retrospective study on a cohort of outpatient AA patients using the MDRD and MDRDrace removed and CKD-EPI and CKD-EPIrace removed and their progression to CKD G5 (eGFR <15 ml/min/1.73 m2). 327 patients were analyzed. Median follow-up was 88.1 months (interquartile range, 34.4–129.1). When race was removed from MDRD, 39.9% of patients in CKD G1/2 were reclassified to CKD G3a, 72.6% of patients in CKD G3a would be reclassified to CKD G3b, and 54.1% and 36.4% of patients would be reclassified from CKD 3b to CKD G4 and CKD G4 to CKD G5, respectively p < 0.0001 . Comparing the CKD-EPI formula against the MDRD in our cohort, we found that 8.2%, 18.8%, and 11.4% of patients were reclassified from CKD G1/2 to CKD G3a, CKD G3a to G3b, and CKD G3b to CKD G4 respectively. Overall median time to progression to CKD G5 was 137.4 (131.9–142.8) months in patients who were not reclassified and 133.6 (127.6–139.6) months for patients who were reclassified by MDRDrace removed p < 0.288 . Concerns of inequitable access to healthcare have elicited calls to review race-corrected eGFR equations. A substantial number of individuals would have their CKD stage reclassified should have the MDRDrace removed equation be adopted en masse on an AA-only population. The discrepancy is highest at the 45–59 and >60 ml/min/1.72 min2 ranges. This will have tremendous impact on our center’s approach to pharmacological dosing, referral system, best practices, and outcome surveillance. Comprehensive review of the current “race-corrected” eGFR will require a multifaceted approach and adjunctive use of noncreatinine-based approach.

Recipient and Center Factors Associated With Immunosuppression Practice Beyond the First Year After Liver Transplantation and Impact on Outcomes

“…As an exploratory analysis, the estimated glomerular filtration rate (eGFR) in the first 3-y post-LT was calculated using creatinine values reported in UNOS and the 4-variable modification of diet in renal disease equation without race correction. 18,19 Mixed-effects linear regression models assessed the association of regimen at 1 y and average eGFR between years 1-2 and years 2-3, accounting for clinical covariates including average eGFR between LT to year 1.…”

Reviewing Racial Disparities in Living Donor Kidney Transplantation: a Socioecological Approach

“…In fact, many health care institutions have been conscientious of this racialized definition of kidney disease and have used the non-Black eGFR obtained from the CKD-EPI equation for all patients admitted to their hospitals. In a retrospective cohort study of an African-American-only patient population performed by Yap and colleagues [ 43 ], the authors found that a substantial number of patients would be reclassified to higher CKD stages when the race-removed CKD-EPI and race-removed CKD-MDRD equations were used.…”

Prognostic Nutritional Index Predicts Contrast-Induced Nephropathy in Patients with Acute Coronary Syndrome

“…2 The Modification of Diet in Renal Disease (MDRD) formula was used to calculate eGFR. 18 DM was defined as having a known history of diabetes, use of antidiabetic drugs, fasting plasma glucose >126 mg/dL, or HbA1c >6.5%. Dyslipidemia was defined as total fasting cholesterol >200 mg/dl, low-density lipoprotein cholesterol (LDL-C) >130 mg/dl, triglycerides >150 mg/dl, high-density lipoprotein cholesterol (HDL-C) <40 mg/dl, and/or chronic use of lipid-lowering medication.…”